Company intelligence / Profile preview
ABION Inc.
Seoul, Seoul, South Koreaabionbio.com ↗
- Ownership
- Private
- Employees
- ~50
- Development stage
- Other
01
Overview
Clinical stage biopharmaceutical company developing novel therapies for oncology, infectious diseases, and rare diseases, with lead asset ABN401 in Phase II for NSCLC.
- Therapeutic areas
- OncologyInfectious Diseases
- Modalities
- Small molecules (e.g., tyrosine kinase inhibitors)Monoclonal antibodies (mAbs)Antibody fusion proteinssiRNA therapeuticsInterferons
- Industry
- Biotech
02
Drug pipeline
6 assets5 more assets in the full pipeline.
03
Partnerships
Strong partnerships with domestic and international biopharma companies (names not specified)
Beyond the preview
Go deeper on ABION Inc..
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ABION Inc..